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Hypothesis. Repeated epithelial cell injury secondary to viruses such as Epstein Barr and subsequent dysfunctional repair may be
central to the pathogenesis of IPF. In this observational study, we evaluated whether a combination of standard and anti-viral
therapy might have an impact on disease progression. Methods. Advanced IPF patients who failed standard therapy and had
serological evidence of previous EBV, received ganciclovir (iv) at 5mg/kg twice daily. Forced vital capacity (FVC), shuttle walk test,
DTPA scan and prednisolone dose were measured before and 8 weeks post-treatment. Results. Fourteen patients were included.
Afterganciclovir,eightpatientsshowedimprovementinFVCandsixdeteriorated.Themedianreductionofprednisolonedosewas
7.5mg (44%). Nine patients were classiﬁed “responders” of whom four showed an improvement in all four criteria, while three
of the ﬁve “non-responders” showed no response in any of the criteria. Responders showed reduction in prednisolone dosage
(P = .02) and improved DTPA clearance (P = .001). Conclusion. This audit outcome suggests that 2-week course of ganciclovir
(iv) may attenuate disease progression in a subgroup of advanced IPF patients. These observations do not suggest that anti-viral
treatmentisasubstituteforthestandardcare,however,suggeststheneedtoexploretheeﬃcacyofganciclovirasadjunctivetherapy
in IPF.
1.Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is an increasingly
common disease with a poor prognosis. Standard therapy
has little or no impact in patients with advanced disease.
The emerging hypothesis for the pathogenesis of IPF is of
repeated epithelial cell injury leading to ﬁbrogenesis and
dysregulated repair [1]. The cause of repeated epithelial cell
injury has received little attention.
Herpesviruses provide a potential source of repeated
epithelialcellinjury.Aroleforviruses,especiallyforEpstein-
Barr virus (EBV) in the pathogenesis of IPF has been
suggested by serological and tissue based studies [2–4].
We have previously demonstrated the presence of EBV
DNA in surgical samples taken from IPF patients [4]. EBV
antigens have been localised by immunohistochemistry to
type II alveolar cells [4]. Animal models have showed that
a Herpesvirus can act as a cofactor in the development of
pulmonary ﬁbrosis [5]. Mora and colleagues showed that
Herpesvirus induced ﬁbrosis in a conditioned host and
removal of a viral injury attenuated lung ﬁbrosis [6].
We hypothesised that a combination of standard treat-
ment and antiviral therapy may have an impact on disease
progression in IPF. The aim of this pilot study was to
determine the eﬃcacy of intravenous (iv) Ganciclovir in a
subgroup of advanced IPF patients unresponsive to standard
therapy.
2. Methods
2.1. Patients. Between 1996 and 2000 we studied patients
with advanced progressive IPF patients who were progres-
sively deteriorating in spite of standard therapy, including2 Pulmonary Medicine
Prednisolone, Azathioprine and Cyclosporin. All patients
had evidence of previous EBV infection based on EBV-IgG
serology detected using indirect immunoﬂuorescence. All
patients had ﬁnger clubbing, late inspiratory crackles, and
restrictive lung function studies. The diagnosis of IPF was
supported by a typical HRCT appearance (n = 14) and/or
diagnostic lung biopsy (n = 3) [7]. Blinded histological
review conﬁrmed the presence of usual interstitial pneumo-
nia.
2.2. Treatment. Patients were oﬀered open label treatment
with Ganciclovir (Cytovene Roche Pharmaceuticals, Basel
Switzerland) given intravenously at 5mg/kg twice daily for
ap e r i o do f2w e e k s .
2.3. Clinical Measures. Before and 8 weeks after treatment,
lung function, exercise tolerance, DTPA clearance and pred-
nisolone dosage were measured as four key clinical response
markers. An improvement in three of these four parameters
was considered to represent a positive therapeutic response
and this patient was deﬁned as a “responder”.
Lung Function. Spirometry best of 3 eﬀorts within 5%
(Gould wet spirometer) was measured. Calibration of the
equipment was performed on a daily basis prior to the
commencement of the procedure. A minimum of three
values with less than 5% variability was required; the best
response was recorded. Carbon monoxide lung transfer
factor (TLCO, corrected for haemoglobin) and coeﬃcient
(KCO) were measured according to ATS guidelines [7]a n d
expressed as percentages of the predicted values calculated
according to sex, weight, and age.
Exercise Tolerance. This was assessed by the shuttle walk test,
validatedpreviouslyinIPFpatients[8].Inbrief,thisinvolved
thepatientwalkinga10mcourseatincreasingspeed.Marker
cones positioned 0.5m from each end avoided the need
for abrupt change in direction. The walking speed, which
steadily increased, was controlled by audio signals played
from an audio player. The test was terminated when (a) the
patient was unable to maintain the required speed due to
breathlessness(b) the operator deemed the patient had failed
to complete a shuttle in the time allowed (more than 0.5m
away from the cone when the bleep sounded) or (c) the
patient attained 85% of the predicted maximal heart rate.
DTPA Scan. 99mTc-DTPA was aerosolised using pressurised
air (Aerotech II nebuliser, CIS-US, Bedford, MA, USA).
Patients were seated in front of a gamma camera while
inhaling the 99mTc-DTPA through a mouthpiece during tidal
breathing. The mouthpiece contained a one-way valve and
the patients wore a nose clip. Inhalation continued for 5min
or until a suitable count rate was detected over the lungs.
Images were then taken for 60 minutes by a gamma camera
withageneral-purposecollimator(StarcamGeneralElectrics
Medical Systems, USA). Images were acquired at an image
resolution of 64 × 64 using frame duration of 20 seconds
for at least the ﬁrst 15 minutes. Regions of interest in both
lungs were acquired and subtraction of background activity
was performed through identiﬁcation of a region between
the kidneys or in the shoulders. The rate of radionucleotide
disappearance from the lung was used to calculate solute
clearance. Clearance rates from each patient referred to
both monoexponential and biexponential clearance analysis.
Curve stripping was used to separate the two components
of the biexponential disappearance curves. The contribution
of the slow component to the early part of the curve was
calculated and subtracted out, isolating the fast component.
Four DTPA variables were considered. These were half
times for the fast component and the slow component of the
biexponential curve, the fraction of the tracer cleared by the
fast component and the half time from a monoexponential
approximation to the early part of the curve. The half
time from a monoexponential approximation to the ﬁrst 15
minutes of the curve was also calculated. The normal half
time value for this parameter was greater than 45 minutes.
An exponential ﬁt was derived from the ﬁrst 15 minutes of
the curve and the half time for clearance of the DTPA from
the lungs was determined [9–11].
Prednisolone Dose. The ability to reduce Prednisolone in
2.5mg steps was based upon the patients’ symptoms and
lung function.
A lung function technician and radiologists who were
blind to the patients underlying therapy or clinical condition
performed the assessment of lung function, exercise toler-
ance and DTPA clearance.
2.4. Statistical Analysis. This was an exploratory study and
no formal power calculation was made. The data were
presented as means and comparisons made using paired
t-tests. A value of P<. 05 was accepted as statistically
signiﬁcant.
3. Results
Fourteen patients (5 males, 9 females mean age 58 years (41–
73) were oﬀered therapy based on disease progression and
EBV seropositivity (Table 1).
All patients showed a restrictive defect (mean FEV1/FVC
ratio86%)withreductioninlungvolumes(meanFVC1.73L
(52% predicted) (range 0.71–3.35L), TLC at 59% predicted
(range 2.1–4.1L)) and an impairment of transfer factor
(mean DLCO 3.42ml/min/mmHg (44% predicted), range
1.22–5.6) (Figure 1).
Nine of the 14 patients were classiﬁed as “responders”
(mean age 56.3 years (41–73), 2 male) with four showing
an improvement in all four criteria. In the non-responders
group (n = 5, mean age 61 years (range 57–66 years), 2
female) three of the ﬁve showed no response in any of the
parameters used. Although females appeared more likely to
respond, a chi-square test did not suggest a gender diﬀerence
(P = .2).
Responders had a signiﬁcant reduction in Prednisolone
dosage and improvement in DTPA clearance (P = .02 and
P = .001, resp.) (Figure 1). Responders tended to be youngerPulmonary Medicine 3
Table 1: Patient demographics.
Patient Sex Age Method of
diagnosis∗
Forced vital
capacity (L)
Total lung
capacity (L)
DLCO
(mL/min/mmHg)
Response to
treatment
Outcome
(after treatment)
1 M 66 Biopsy/HRCT 2.05 3.69 3.07 Responder Dead (9 months)
2 F 51 HRCT 1.21 2.11 # Responder Alive
3 F 41 Biopsy/HRCT 1.63 3.3 3.93 Responder Alive
4 F 71 HRCT 2.09 3.59 5.61 Responder Dead (30 mths)
5 F 62 HRCT∗ 0.71 ## Responder Transplanted (2 mths)
6 M 60 HRCT 2.52 4.18 4.3 Nonresponder Dead (5 mths)
7 F 66 HRCT 1.07 2.89 2.94 Nonresponder Dead (7 mths)
8 F 60 HRCT 1.75 3.02 1.39 Nonresponder Dead (6 mths)
9 M 57 HRCT∗ 1.72 2.99 2.58 Nonresponder Transplanted (4 mths)
10 F 50 HRCT∗ 1.43 2.59 # Responder Transplanted (4 mths)
11 F 46 HRCT∗ 1.25 2.39 3.9 Responder Transplanted (11 mths)
12 M 61 HRCT∗ 1.88 3.86 3.3 Nonresponder Transplanted (2 mths)
13 F 73 HRCT 1.60 3.17 3.2 Responder Dead (9 mths)
14 M 47 Biopsy/HRCT 3.35 ## Responder Alive
∗All patients had a diagnostic HRCT. Three patients had diagnostic histology concurrently by VATS (video assisted thoracoscopy) and a further ﬁve patients
had the histological conﬁrmation conﬁrmed in the explanted lung after transplantation.
#Patients were unable to perform testing.
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Figure 1: Patient characteristics following Ganciclovir. ∗Some patients were unable to perform the test due to breathlessness.
than non-responders (Mean age 56.3 years versus 60.8 years,
P = .21). No signiﬁcant adverse eﬀects were observed from
the therapy.
Followingtreatmentthepatientsweresubjecttoafollow-
up, for up to 12 months. Of the nine responders, ﬁve
underwent lung transplantation and six died. In the non-
responder group two received lung transplantation and three
had died at the end of the follow-up period (see Table 2).
4. Discussion
The long-term prognosis of progressive IPF is very poor, as
is clear in this cohort of patients. This observational report
suggests that a 2-week course of intravenous Ganciclovir
may temporarily attenuate disease progression in a subgroup
of patients with advanced IPF. This adds to the emerging
evidence that a viral cofactor may contribute to disease
progression in some patients, and provides a framework for
the planning of a randomised treatment study.
Vergnon and colleagues ﬁrst implicated EBV in the
aetiology of IPF when serological testing identiﬁed elevated
levels of IgG and IgA against viral capsid antigen (VCA) in
these patients [2]. Studies utilising both immunohistochem-
istry and PCR have conﬁrmed this association. Subsequently
Tsukamoto and colleagues demonstrated that the presence
of EBV latent membrane protein in the lung tissue of IPF4 Pulmonary Medicine
Table 2: Summary of the non-responders (n = 5) and responders (n = 9) before and after Ganciclovir. Comparison by paired t-test.
Parameter Responders Nonresponders
Pre Post P value Pre Post P value
FVC (litres) 1.70 1.85 .046 1.76 1.37 .08
DTPA (minutes) 22.4 28.2 .001 25.2# 17∗ @
Shuttle (meters) 286 307 .08 260 273 .52
Prednisolone (mg) 19 10 .02 21 13.5 .95
∗3 of the 5 patients were unable to perform test.
#1 of the 4 patients was unable to perform test.
@No paired samples available for statistical analysis.
patients was associated with rapid disease progression [12].
A n i m a lm o d e ls t u d i e ss u g g e s tt h a tE B Va l o n ed o e sn o tc a u s e
pulmonary ﬁbrosis but it may represent a cofactor in disease
progression or act as a source of injury in a predisposed host
[5]. In IFN-gamma receptor-deﬁcient mice, Herpes viral
infectionledtopulmonaryﬁbrosis[6].Theseauthorsfurther
showed that antiviral therapy controlled virus replication
during chronic infection and prevented lung ﬁbrosis [6].
Our cohort included patients with progressive IPF with
a mean DLCO of 40% predicted and an overall survival of
8 months. Six patients died and 5 underwent transplant.
Therefore, a dramatic response to treatment should not be
anticipated. However, the short-term impact of Ganciclovir
was encouraging in improving surrogate markers of disease
progression. As expected the clinical response seen in the
nine responders was modest. Treatment studies in advanced
IPF are diﬃcult because speciﬁc measures of disease severity
or short-term disease progression are limited. This is a
particular problem in an open observational study. In an
a t t e m p tt oo v e r c o m et h i sp r o b l e mw ec h o s e4s u r r o g a t e
markers (vital capacity, DTPA clearance, exercise tolerance
and prednisolone dosage). Lung function, DTPA scans and
exercise capacity parameters have previously been used
individuallyasmarkersofdiseaseactivityandprognosis[11].
The shuttle walk test was chosen as the exercise test because
it has previously been shown to correlate with VO2max [8].
Thistestincontrasttothesix-minutewalktestislessaﬀected
by the subjective eﬀorts, which is likely to occur in a study
of short duration as presented here. Each parameter has its
individual merit, although no one test is ideal. We believe
that the combination of these tests results in an improved
objective overview of the response. Similarly, we did not
measure serial DLCO because of variability and the inability
of patients to perform the tests at the requested time due to
severity of their illness.
Tissuebasedstudiessuggestthat50%ofIPFpatientshave
EBV [3]. More recently it has been shown that Herpesvirus
DNA is consistently found in lung tissue from patients with
IPF and that EBV and human Herpes virus 8 show viral
antigen primarily in the airway epithelial cells [13]. One
diﬃculty in interpreting our data is absence of a surrogate
marker of tissue speciﬁc viral activity. The patients were too
unwell to undergo further biopsies and therefore treatment
had to be empirical. Patients were selected on the basis of
having positive serological (IgG) testing for EBV.
King and colleagues have correlated the ﬁbroblastic foci
observed in IPF biopsies as a survival marker [1]. The
persistent epithelial damage and unrelenting proliferation
of ﬁbroblasts need to be targeted in order to arrest the
progressive disease and fatal outcomes associated with IPF
[1]. EBV infection has been shown to persist in patients with
IPF and may contribute to epithelial damage; its role in the
pathogenesisofIPFrequirescloserscrutiny.Theshortcourse
of intravenous Ganciclovir in patients with advanced disease
in this study may not have allowed suﬃcient time to produce
more signiﬁcant results. Future studies should focus on oral
treatment in a cohort of patients with less advanced disease.
This study provides interesting preliminary data. How-
ever, to progress the thesis, a study including controlled
group data would be required to strengthen the signiﬁ-
cance of the observations presented. Observation studies
as presented are prone to bias in patient selection. It is
also uncertain whether the duration of therapy chosen was
optimal. A 2 week course of intravenous Ganciclovir was
chosen for practical reasons. It is possible that a prolonged
course of oral therapy may have a more beneﬁcial eﬀect.
A single short course of treatment with intravenous
Ganciclovir produced a temporary beneﬁt in a subgroup
of patients with progressive and treatment-resistant IPF
patients. We emphasise that our ﬁndings do not suggest
that antiviral therapy is a panacea or substitute for standard
care. The observations are interesting in that the data
suggests that a viral cofactor may contribute to disease
progression and provide a basis for the planning of a
randomised controlled study. It is possible that maintenance
oral valganciclovir might maintain any beneﬁt arising from
intravenous Ganciclovir.
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